Extended Data Fig. 2: Secondary validation experiments of the screen highlight MEN1 and SUZ12 as candidate hits.
From: Genome-wide CRISPR screen identifies Menin and SUZ12 as regulators of human developmental timing
a, Schematic of the genetic approach of the secondary validation experiments and the results of PAX6+ (%) at day 4 normalized to NT control (n = 2 independent differentiations for SLC52A2, SMPX, GRPEL2; n = 4 for SUZ12, ZSWIM8, EED, GLI2, KRT15, DENND4B, PPP1R18; n = 3 for the rest). Data are the mean ± s.e.m. b, DepMap analysis on the top ranked hits was performed as described in the ‘DepMap analysis’ method section. Gene cluster that includes the most screen hits was shown. c, Schematic of the pharmacological approach of the secondary validation experiments and the results of PAX6+ (%) at day 4 normalized to NT control (n = 2 for Oligo and Dev; n = 3 for the rest). Small molecule inhibitors are coloured according to their respective targeting pathways. Details on the inhibitors and their doses used can be found in Supplementary Table 3. Data are the mean ± s.e.m. d, Expression of neural markers (PAX6 and ZBTB16) in drug combinations versus DMSO vehicle control at day 4 of neuroectoderm differentiation, assessed by flow cytometry. VTP, VTP50469 (Menin-MLL inhibitor); PRT, PRT4165 (PRC1 inhibitor); TAZ, Tazemetostat (PRC2 inhibitor).
